D/E 0.02 — less debt than most Healthcare peers (≈25th pctile)
P/E17.8xA-
P/E 17.8 — cheaper than most Healthcare peers (≈25th pctile)
PEG1.49B
PEG 1.49 — acceptable premium for growth
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 76.9
Quality0.69
Growth0.95
Value0.70
Entry · Margin of safety
52-week rangeMid-range
24% off the 12-month high
vs DCF fair value1% belowest. fair value ~$78
Quality signals · context only
Gross profitability39% · B+gross profit ÷ total assets (Novy-Marx)
ROIC8.9% · Breturn on invested capital — not score-weighted
Why now
Globus Medical is a compelling growth compounder, leveraging its robust portfolio of spine products and orthopedic trauma solutions to drive consistent expansion in musculoskeletal healthcare. With a strong 16.7% FY YoY revenue growth and an impressive 18.9% profit margin, the company is efficiently converting its market leadership into substantial cash flow, evidenced by $610m in TTM FCF. The core thesis rests on the persistent, growing demand for advanced surgical solutions for musculoskeletal disorders, which GMED is uniquely positioned to capitalize on through its specialized offerings.
Moat
GMED's durable edge stems from its highly specialized product lines, particularly its traditional fusion implants and motion preservation technologies within spine products, as well as its orthopedic trauma solutions. These devices require significant R&D investment, rigorous regulatory approvals, and specialized surgical expertise for adoption, creating high barriers to entry for competitors. The company's focus on innovative solutions for complex musculoskeletal disorders ensures sticky customer relationships and pricing power within its niche.
Risk
The primary risk for GMED lies in the highly competitive landscape of the medical devices sector, particularly within its core spine products segment, where pricing pressure could erode its impressive 18.9% profit margin. While current debt is minimal (0.02 debt-to-equity), a significant slowdown in its 16.7% revenue growth could expose its valuation, with a 52-week high of $101.4 suggesting previous investor optimism that has since cooled. A sustained deceleration in revenue growth or a noticeable contraction in profit margins would confirm the bear case.
Horizon
1-3 yr $107.42 (12-analyst consensus) — fundamentals + valuation re-rating. 5 yr $157.27 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $233.30 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · GMED
$
%
%
Shares to buy
26
Position size
$1,993
4.0% of portfolio
Stop price
$57.48
25% below $76.64
$ at risk if stopped
$498.16
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Globus Medical, Inc. (GMED): score, valuation & FAQ
Globus Medical, Inc. (GMED) is a Medical Devices company that scores 76.9 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (A-), P/E (A-) and Rev (B+). On valuation, GMED sits close to our DCF fair-value estimate (within a few percent).
Is GMED a good stock to buy?
Bull Rankings scores GMED 76.9 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by D/E (A-), P/E (A-) and Rev (B+). A score is a quantitative screen of Globus Medical, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does GMED score 76.9 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). GMED earns its highest marks on D/E (A-), P/E (A-) and Rev (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is GMED overvalued or undervalued?
Based on $76.64, GMED sits close to our DCF fair-value estimate (within a few percent). It trades at a 17.8x× P/E (graded A-). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in GMED?
The primary risk for GMED lies in the highly competitive landscape of the medical devices sector, particularly within its core spine products segment, where pricing pressure could erode its impressive 18.9% profit margin. While current debt is minimal (0.02 debt-to-equity), a significant slowdown in its 16.7% revenue growth could expose its valuation, with a 52-week high of $101.4 suggesting previous investor optimism that has since cooled. A sustained deceleration in revenue growth or a noticeable contraction in profit margins would confirm the bear case.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.